| February 2010, Volume 5, No. 2 |
| RSV: Prevention of Disease |
|
Learning Objectives
-
Describe the epidemiology of RSV.
-
Summarize the risk factors for RSV.
-
Explain the immunity of RSV after infection.
-
Outline the history of immunoprophylaxis.
-
Review the updated AAP recommendations.
-
Determine the relationship between the FDA package insert statements and the AAP.
-
Relate the rate of the nosocomial RSV infection.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
H. Cody Meissner, MD, FAAPCurrent Source of Funding From Research Grant: Multicenter Clinical Trial. This issue does not contain a discussion of unapproved/investigative use of a commercial product/device. |
Caroline B. Hall, MD, FAAPCurrent Source of Funding From Research Grant: MedImmune, Inc. This issue does not contain a discussion of unapproved/investigative use of a commercial product/device. |
Joseph A. Bocchini, MD, FAAPDr. Bocchini disclosed no financial relationship relevant to this issue. This issue does not contain a discussion of unapproved/investigative use of a commercial product/device. |
